Biologic therapies in psoriasis: A new therapeutic approach
Authors:
- Paolo GisondiPGPaolo Gisondi
- Giampiero GirolomoniGGGiampiero Girolomoni
- 1 September 2007
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 6 (8) , 515-519
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Proceedings of the National Academy of Sciences, 2005
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Psoriasis treatment: current and emerging directed therapiesAnnals of the Rheumatic Diseases, 2005
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque PsoriasisArchives of Dermatology, 2005
- Safety and efficacy study on etanercept in patients with plaque psoriasisBritish Journal of Dermatology, 2005
- Targeting Tumor Necrosis Factor-α in the Therapy of PsoriasisCurrent Drug Targets - Inflammation & Allergy, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque PsoriasisNew England Journal of Medicine, 2003
- PsoriasisThe Lancet, 2003